MAPT and Alzheimer disease: Consequently, CaM could aid in differential diagnosis in the differential diagnosis of familial FTD, providing complementary value to established core AD biomarkers, such as phosphorylated tau species, MTBR-tau isoforms, and Aβ42/40 ratio (57).